Aureon Laboratories Announces Name Change for Existing Post-Surgical Prostate Cancer Recurrence Test

Commercially Available Since February 2006, Post-Op Px(TM) is the First Diagnostic Test to Predict Prostate Cancer Recurrence

        Print
| Source: Aureon Laboratories, Inc.

YONKERS, N.Y., March 5, 2010 (GLOBE NEWSWIRE) -- Today, Aureon Laboratories, Inc. announced a new name for its post-prostatectomy, prognostic test available for patients who have undergone surgery to treat their prostate cancer. Commercially available since February 2006, Post-Op Px™ (previously known as Prostate Px), was the first diagnostic test to predict prostate cancer recurrence and disease progression post treatment. For over four years, Post-Op Px has integrated tissue, clinical and molecular information to enable physicians and their patients to make more informed decisions about post-surgical, adjuvant therapies. In addition, Aureon's other commercially available prognostic test, Prostate Px+, was launched in 2008 and uses biopsy tissue to predict disease progression (metastasis, progression through a castrate state) at diagnosis, prior to treatment.

"We're excited to announce the new name for our post-prostatectomy test and believe Post-Op Px better reflects its clinical utility in the marketplace," said Robert Shovlin, President and CEO of Aureon Laboratories. "Aureon's prognostic tests have been well received in the marketplace and we plan to extend and expand test capabilities in the future."

Post-Op Px is a prognostic test that utilizes a patented systems pathology approach to analyze prostatectomy tissue by combining cellular, molecular and clinical information to provide a thorough and more accurate picture of each patient's individual risk. Aureon's Post-Op Px is based on data from a cohort of 758 patients and is supported by peer-reviewed research papers in the Journal of Clinical Oncology and the Journal of Clinical Investigation. In addition, at the recent International Robotic Urology Symposium (IRUS) in Las Vegas, Aureon presented new data that demonstrated Post-Op Px is more accurate at predicting prostate cancer disease progression following prostatectomy than histology-based high-risk features such as extracapsular extension or positive surgical margins.

About Aureon Laboratories

Aureon Laboratories' mission is to enable personalized patient care through predictive pathology. Aureon has developed a high throughput systems pathology technology platform to predict individual clinical outcomes through the interrogation of tissue. The platform generates and analyzes an integrated, digital view of clinical findings, tissue micro-anatomy and tissue molecular pathology to determine which combination of features predicts specified individual clinical outcomes. Allied with major cancer centers, Aureon operates a CLIA-certified and CAP-accredited laboratory that provides predictive pathology services to the practicing physician. For more information about Aureon, please visit www.aureon.com or call 1-888-SYS-PATH.

The Aureon Laboratories logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6360

Aureon Laboratories
Jason Alter, Ph.D.
914-377-4036